What is the effectiveness of the new weapon for myeloma patients: cetuximab? Listen to what the user has to say

　　Multiple Myeloma(MM),an currently incurable hematologic malignancy,has long plagued patients,especially those facing multiple relapses and resistance to traditional therapies.However,the treatment landscape witnessed a milestone shift in 2025.Isatuximab-irfc(Brand Name:Sarclisa),a humanized monoclonal antibody targeting CD38,was approved by China's NMPA in early 2025 not only for Relapsed/Refractory MM(RRMM)but also expanded to Newly Diagnosed MM(NDMM)patients ineligible for transplant.As the first and currently only anti-CD38 monoclonal antibody approved for use in combination with the standard VRd regimen,its launch marks the entry of MM whole-course management into a new era of precision immunotherapy,providing a powerful weapon for both relapsed/refractory and newly diagnosed patients to extend survival and improve quality of life.

　　1.Mechanism of Action and Clinical Efficacy:Multi-Pronged Attack,Deep Remission

　　Isatuximab is not a traditional cytotoxic agent.By binding with high affinity to CD38 molecules on the surface of myeloma cells,it launches a"triple anti-tumor offensive":

　　Direct Apoptosis Induction:Binding activates intracellular apoptotic signaling pathways,forcing tumor cells to undergo programmed cell death.

　　Immune-Mediated Killing:It significantly activates Natural Killer(NK)cells and macrophages,precisely eliminating cancer cells via Antibody-Dependent Cellular Cytotoxicity(ADCC)and Antibody-Dependent Cellular Phagocytosis(ADCP).

　　Enzymatic Activity Inhibition:It inhibits the cyclase activity of CD38,blocking immune evasion and adhesion functions of tumor cells,thereby disrupting their survival microenvironment.

　　Clinical Evidence:In the pivotal ICARIA-MM study,for patients with RRMM who had received at least two prior lines of therapy(including lenalidomide and a proteasome inhibitor),the"Isatuximab+Pomalidomide+Dexamethasone"(Isa-Pd)regimen significantly prolonged Progression-Free Survival(PFS)and improved Overall Response Rates(ORR)compared to Pd alone.Crucially,this regimen significantly increased rates of Minimal Residual Disease(MRD)negativity,indicating deeper remission and longer survival benefits.Furthermore,studies on its combination with VRd(Isa-VRd)for newly diagnosed patients show an expected PFS of up to 90 months(approx.7.5 years),promising to redefine the standard of care for first-line treatment and establishing its core role throughout the disease course.

　　2.Patient Usage Experience and Real-World Feedback

　　Based on clinical practice and patient feedback,the treatment experience with Isatuximab features:

　　Administration:Delivered via intravenous infusion.The first infusion takes longer(approx.3-4 hours)for close observation;if well-tolerated,subsequent infusions can be shortened to 1-2 hours,significantly reducing time spent at the hospital and improving convenience.

　　Adverse Event Management:The most common side effects are Infusion-Related Reactions(IRR)such as fever,chills,and dyspnea,mostly occurring during the first infusion.These are largely manageable and mild with standardized pre-medication(antihistamines,antipyretics,and corticosteroids).Hematological toxicities(e.g.,neutropenia)are also common and require regular blood count monitoring and timely intervention.

　　Quality of Life Comparison:Many patients report less fatigue and faster recovery of physical function compared to traditional high-intensity chemotherapy.While individual variations exist,Sarclisa generally maintains daily living capabilities and physical status well while effectively controlling the disease.

　　3.Treatment Prospects and Expert Recommendations

　　With the continuous expansion of indications and accumulation of clinical data,the position of Isatuximab in MM treatment is becoming increasingly solid.Future research continues to explore its use in first-line settings,maintenance therapy,and combinations with novel agents(like bispecific antibodies and CAR-T),promising to further redefine the standard of care for Multiple Myeloma and推动its transition towards a"chronic disease"management model.

　　Conclusion:Scientific Decision-Making,Building a Line of Defense for Life

　　For MM patients,the launch of Isatuximab(Sarclisa)represents not just an additional drug option,but a tangible extension of survival hope.We recommend patients and families:

　　Early Assessment:Consult with hematologists to comprehensively evaluate suitability for Isatuximab-based regimens based on genetic profiles and treatment history,seizing the"golden window"for treatment.

　　Standardized Administration:Strictly follow medical advice for pre-medication and infusion monitoring to maximize efficacy and minimize risks.

　　Mindset Adjustment:Maintain a positive outlook and fully trust in the progress of modern medicine.With the continuous emergence of innovative therapies,every patient has the opportunity to win a longer,higher-quality life and regain control over their life through scientific response and standardized treatment.